Clinical Trial

J04104: Sorafenib in combination with Irinotecan and Erbitux (Cetuximab) for patients who have had disease progression after 2 lines of chemotherapy
 

This study is for patients who have Stage IV metastatic colorectal cancer and their disease progressed after 2 lines of treatment with chemotherapy.

Protocol number: J04104

Type of cancer: Stage IV Metastatic Colorectal Cancer

Phase number: I

Summary:  This is a phase I study for patients with Stage IV metastatic colorectal cancer who have had disease progression after 2 lines of chemotherapy.  The purpose of the study is to find safe doses of sorafenib, in combination with Irinotecan and Cetuximab.

 
 
Contact

Rosalind Walker, RN:  rwalker3@jhmi.edu

 
Return to Clinical Trials